Next Article in Journal
Revealing the Proteome of Motor Cortex Derived Extracellular Vesicles Isolated from Amyotrophic Lateral Sclerosis Human Postmortem Tissues
Previous Article in Journal
Head and Neck Cancer Stem Cell-Enriched Spheroid Model for Anticancer Compound Screening
Review

The Yin and Yang of ACE/ACE2 Pathways: The Rationale for the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients

by 1,2
1
Department of Biomolecular Sciences, University of Urbino “Carlo Bo”, 61032 Urbino, Italy
2
INFN-Gran Sasso National Laboratory, Assergi, 67100 L’Aquila, Italy
Cells 2020, 9(7), 1704; https://doi.org/10.3390/cells9071704
Received: 20 March 2020 / Revised: 10 June 2020 / Accepted: 25 June 2020 / Published: 16 July 2020
The article describes the rationale for inhibition of the renin-angiotensin system (RAS) pathways as specific targets in patients infected by SARS-CoV-2 in order to prevent positive feedback-loop mechanisms. Based purely on experimental studies in which RAS pathway inhibitors were administered in vivo to humans/rodents, a reasonable hypothesis of using inhibitors that block both ACE and ACE2 zinc metalloproteases and their downstream pathways in COVID-19 patients will be proposed. In particular, metal (zinc) chelators and renin inhibitors may work alone or in combination to inhibit the positive feedback loops (initially triggered by SARS-CoV-2 and subsequently sustained by hypoxia independently on viral trigger) as both arms of renin-angiotensin system are upregulated, leading to critical, advanced and untreatable stages of the disease. View Full-Text
Keywords: severe acute respiratory syndrome coronavirus-2; eosinophil; asthma; IL-10; lung fibrosis; hypoxia; hypertension; cardiac dysfunction; renin-angiotensin system; Mas receptor severe acute respiratory syndrome coronavirus-2; eosinophil; asthma; IL-10; lung fibrosis; hypoxia; hypertension; cardiac dysfunction; renin-angiotensin system; Mas receptor
Show Figures

Figure 1

MDPI and ACS Style

Zamai, L. The Yin and Yang of ACE/ACE2 Pathways: The Rationale for the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients. Cells 2020, 9, 1704. https://doi.org/10.3390/cells9071704

AMA Style

Zamai L. The Yin and Yang of ACE/ACE2 Pathways: The Rationale for the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients. Cells. 2020; 9(7):1704. https://doi.org/10.3390/cells9071704

Chicago/Turabian Style

Zamai, Loris. 2020. "The Yin and Yang of ACE/ACE2 Pathways: The Rationale for the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients" Cells 9, no. 7: 1704. https://doi.org/10.3390/cells9071704

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop